Cyxone strengthens team ahead of continued development of the drug projects and the company
Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company is expanding its team with Christin Arrhenius Bokedal as Head of Development for the next step in the development of Cyxone's clinical drug portfolio. Christin will primarily lead and coordinate the preclinical and clinical development programs in the company.Christin Arrhenius Bokedal holds a master degree in pharmacy from Uppsala University. During her career, Christin has accumulated extensive and diverse experience in drug development from her positions within Regulatory Affairs, Quality Assurance,